Dr. Klaus Stöckemann
“When funding innovative ideas, you have to be bold enough to take the first step, even alone, and swim against the flow.”
Klaus Stöckemann is a co-founder and Managing Director of Peppermint VenturePartners GmbH and Managing Partner of Peppermint Charité Biomedical Fund.
Prior to the launch of Peppermint VenturePartners, he was a general partner in the international healthcare venture team of 3i plc. During the time at 3i he was responsible for more than 12 investments. His track record at 3i included not only IPOs of companies such as Epigenomics, Jerini and Santhera, but also the trade sales of Evotec Neuroscience, Amaxa and Elbion.
Prior to his tenure at 3i, Stöckemann held leading positions in research as well as in business development at major pharma corporations such Schering AG and ASTA Medica (a Degussa-Hüls group subsidiary).
Klaus Stöckemann was a member of the supervisory boards or boards of Combinature, Epigenomics, Jerini, Amaxa, Immatics, as well as IntelliDx and Zonare in the United States. He is currently the Chairman of the boards of Humedics GmbH, Emperra GmbH, Caterna Vision, and is a board member of Implandata Ophthalmic Products GmbH.
Stöckemann’s more than 14-year experience in the venture capital industry makes him an experienced venture capital investor.
He has a Ph.D in biology and pharmacology from the University of Mainz, as well as an MBA from WHU/Kellogg, Northwestern University in the United States.